Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

about

7-Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir.Effectiveness, Safety, and Tolerability of a Switch to Dual Therapy with Dolutegravir Plus Cobicistat-Boosted Darunavir in Treatment-Experienced Patients with Human Immunodeficiency Virus

P2860

Q55554218-DAEEC863-7857-4EAB-A0B4-1D661E2D3203 Q57124195-5262C4CE-A99C-480B-A0B5-45437267F85C

P2860

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

Item

http://www.wikidata.org/entity/Q47301806

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@en

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@nl

type

Item

label

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@en

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@nl

prefLabel

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@en

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@nl

P1476

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

@en

P2093

Amedeo F Capetti

http://www.w3.org/2001/XMLSchema#string

Giuliano Rizzardini

http://www.w3.org/2001/XMLSchema#string

Laura Paladini

http://www.w3.org/2001/XMLSchema#string

Maria V Cossu

http://www.w3.org/2001/XMLSchema#string

P2860

Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients

Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort

Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025.

E138A in HIV-1 reverse transcriptase is more common in subtype C than B: implications for rilpivirine use in resource-limited settings.

Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects.

Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.

P304

65-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14656566.2017.1417984

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29246084

http://www.w3.org/2001/XMLSchema#string

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

about

P2860

P2860

Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698